Review



recombinant il 24  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress recombinant il 24
    Recombinant Il 24, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+il+24/Animal-Free+IL-24%2C+Mouse/pm42228927-59-19-23
    Average 94 stars, based on 1 article reviews
    recombinant il 24 - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: IL-24 ameliorates cognitive dysfunction via the inhibition PERK-eIF2α Signaling pathway in Alzheimer's disease.
    Article Snippet: The role of inflammation in the etiology and progression of Alzheimer’s disease (AD) has attracted increasing attention; however, the effect of peripheral adaptive immune cells and IL-24 expression on amnestic mild cognitive impairment (aMCI)/AD remains unclear.. We detected a reduction in CD4 central memory T cells (TCM) and an increase in effector memory T cells (TEM) in AD compared with aMCI and controls.. CD4 T cells from patients with AD showed enhanced proliferation, reduced secretion levels of IL-24, and increased secretion levels of IFN-γ and TNF-α.

    Article Title: The dual pathogenic role of IL-24 in sepsis: Coupling bacterial dissemination with inflammatory amplification as a therapeutic target.
    Article Snippet: .. One end of a capillary tube (#5-000-2005, Drummond Scientific, USA) was filled with either PBS or 10 μg/ mL recombinant IL-24 (rIL-24; #HY-P700200AF, MCE, USA)/recombinant IL-19 (rIL-24; #HY-P7213, MCE) diluted in PBS, and the other end was sealed with paraffin. ..



    Similar Products

    94
    MedChemExpress recombinant il 24
    Recombinant Il 24, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+il+24/Animal-Free+IL-24%2C+Mouse/pm42228927-59-19-23
    Average 94 stars, based on 1 article reviews
    recombinant il 24 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Proteintech well plate
    Well Plate, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+il+24/Animal-free+Recombinant+Human+IL-4/pmc12862018-221-55-51
    Average 94 stars, based on 1 article reviews
    well plate - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress recombinant mouse il 1β
    Verification of the therapeutic effect of PM in delaying the senescence of chondrocytes. (a) Schematic diagram of primary chondrocyte isolation and in vitro experimental design. (b) Representative images of brightfield, Alcian blue, Safranin O, and Toluidine blue staining of chondrocytes. (c, d) Protein levels of p16 and SLPI detected by Western blot (WB) <t>after</t> <t>IL-1β</t> treatment (c) or Slpi overexpression (OE-Slpi; d). (e, f) Representative images of SA-β-gal staining (e) and quantitative analysis of positive cells (f) in OE-negative control (OE-NC) or OE-Slpi chondrocytes. (g, h) Representative images of SA-β-gal staining (g) and quantitative analysis of positive cells (h) in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (i, j) Quantitative real-time PCR (qPCR) analysis of p16 and MMP3 mRNA expression in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (k, l) Representative images of SA-β-gal staining (k) and quantitative analysis of positive cells (l) in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. (m, n) qPCR analysis of p16 and MMP3 mRNA expression in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. Data are presented as mean ± standard deviation (n = 3 independent experiments). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant. (Student’s t -test: f; ANOVA: h, i, j, l, m, n). OE, overexpression; NC, negative control.
    Recombinant Mouse Il 1β, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+il+24/Animal-Free+IL-24%2C+Mouse/pmc12809408-197-26-31
    Average 94 stars, based on 1 article reviews
    recombinant mouse il 1β - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    R&D Systems human il 24 protein r d systems
    Verification of the therapeutic effect of PM in delaying the senescence of chondrocytes. (a) Schematic diagram of primary chondrocyte isolation and in vitro experimental design. (b) Representative images of brightfield, Alcian blue, Safranin O, and Toluidine blue staining of chondrocytes. (c, d) Protein levels of p16 and SLPI detected by Western blot (WB) <t>after</t> <t>IL-1β</t> treatment (c) or Slpi overexpression (OE-Slpi; d). (e, f) Representative images of SA-β-gal staining (e) and quantitative analysis of positive cells (f) in OE-negative control (OE-NC) or OE-Slpi chondrocytes. (g, h) Representative images of SA-β-gal staining (g) and quantitative analysis of positive cells (h) in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (i, j) Quantitative real-time PCR (qPCR) analysis of p16 and MMP3 mRNA expression in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (k, l) Representative images of SA-β-gal staining (k) and quantitative analysis of positive cells (l) in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. (m, n) qPCR analysis of p16 and MMP3 mRNA expression in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. Data are presented as mean ± standard deviation (n = 3 independent experiments). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant. (Student’s t -test: f; ANOVA: h, i, j, l, m, n). OE, overexpression; NC, negative control.
    Human Il 24 Protein R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+il+24/Recombinant+Human+IL-24+Protein/pmc10086458__gutjnl___2022___327166supp001-224-50-53
    Average 93 stars, based on 1 article reviews
    human il 24 protein r d systems - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    R&D Systems 1965 il
    Verification of the therapeutic effect of PM in delaying the senescence of chondrocytes. (a) Schematic diagram of primary chondrocyte isolation and in vitro experimental design. (b) Representative images of brightfield, Alcian blue, Safranin O, and Toluidine blue staining of chondrocytes. (c, d) Protein levels of p16 and SLPI detected by Western blot (WB) <t>after</t> <t>IL-1β</t> treatment (c) or Slpi overexpression (OE-Slpi; d). (e, f) Representative images of SA-β-gal staining (e) and quantitative analysis of positive cells (f) in OE-negative control (OE-NC) or OE-Slpi chondrocytes. (g, h) Representative images of SA-β-gal staining (g) and quantitative analysis of positive cells (h) in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (i, j) Quantitative real-time PCR (qPCR) analysis of p16 and MMP3 mRNA expression in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (k, l) Representative images of SA-β-gal staining (k) and quantitative analysis of positive cells (l) in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. (m, n) qPCR analysis of p16 and MMP3 mRNA expression in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. Data are presented as mean ± standard deviation (n = 3 independent experiments). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant. (Student’s t -test: f; ANOVA: h, i, j, l, m, n). OE, overexpression; NC, negative control.
    1965 Il, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+il+24/Recombinant+Human+IL-24+Protein/pmc10086458__gutjnl___2022___327166supp001-224-56-61
    Average 93 stars, based on 1 article reviews
    1965 il - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress recombinant human il
    Fig. 4. Regulation <t>of</t> <t>IL-24</t> by transcription factor AP-1. (A) RT-qPCR analysis of IL-24 mRNA expression levels in human nasal mucosal tissue samples (left, n=15) and ELISA detection of IL-24 levels in human serum samples (right, n=5). (B) Measurement of IL-24 mRNA in nasal mucosal and serum samples from HDM-sensitized AR mouse models (n=4). (C) Positive correlation between IL-24 expression and FOS and JUN levels in human nasal mucosal tissue samples. (D) Positive correlation between IL-24 expression and FOS and JUN levels in mouse nasal mucosal tissue samples. (E) Predicted AP-1 binding sites in the IL-24 promoter region and design of fragments for subsequent ChIP analysis. (F) AP-1 binding motif. (G) Confirmation of RT-qPCR products in ChIP assays using nucleic acid electrophoresis. (H) ChIP-seq data from the ENCODE database verifying AP-1 binding peaks on the promoter region of IL-24 in A549 cells. Error bars represent mean ± SD. Ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.
    Recombinant Human Il, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+il+24/Animal-Free+IL-24%2C+Human/pm39826453-94-0-6
    Average 93 stars, based on 1 article reviews
    recombinant human il - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    96
    R&D Systems microparticles 24 carriers
    Fig. 4. Regulation <t>of</t> <t>IL-24</t> by transcription factor AP-1. (A) RT-qPCR analysis of IL-24 mRNA expression levels in human nasal mucosal tissue samples (left, n=15) and ELISA detection of IL-24 levels in human serum samples (right, n=5). (B) Measurement of IL-24 mRNA in nasal mucosal and serum samples from HDM-sensitized AR mouse models (n=4). (C) Positive correlation between IL-24 expression and FOS and JUN levels in human nasal mucosal tissue samples. (D) Positive correlation between IL-24 expression and FOS and JUN levels in mouse nasal mucosal tissue samples. (E) Predicted AP-1 binding sites in the IL-24 promoter region and design of fragments for subsequent ChIP analysis. (F) AP-1 binding motif. (G) Confirmation of RT-qPCR products in ChIP assays using nucleic acid electrophoresis. (H) ChIP-seq data from the ENCODE database verifying AP-1 binding peaks on the promoter region of IL-24 in A549 cells. Error bars represent mean ± SD. Ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.
    Microparticles 24 Carriers, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+il+24/Recombinant+Mouse+IL-4+Protein/pm39465979-56-8-17
    Average 96 stars, based on 1 article reviews
    microparticles 24 carriers - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant human il24
    Fig. 4. Regulation <t>of</t> <t>IL-24</t> by transcription factor AP-1. (A) RT-qPCR analysis of IL-24 mRNA expression levels in human nasal mucosal tissue samples (left, n=15) and ELISA detection of IL-24 levels in human serum samples (right, n=5). (B) Measurement of IL-24 mRNA in nasal mucosal and serum samples from HDM-sensitized AR mouse models (n=4). (C) Positive correlation between IL-24 expression and FOS and JUN levels in human nasal mucosal tissue samples. (D) Positive correlation between IL-24 expression and FOS and JUN levels in mouse nasal mucosal tissue samples. (E) Predicted AP-1 binding sites in the IL-24 promoter region and design of fragments for subsequent ChIP analysis. (F) AP-1 binding motif. (G) Confirmation of RT-qPCR products in ChIP assays using nucleic acid electrophoresis. (H) ChIP-seq data from the ENCODE database verifying AP-1 binding peaks on the promoter region of IL-24 in A549 cells. Error bars represent mean ± SD. Ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.
    Recombinant Human Il24, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+il+24/Recombinant+Human+IL-24+Protein/pm39029221-51-0-4
    Average 93 stars, based on 1 article reviews
    recombinant human il24 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    Verification of the therapeutic effect of PM in delaying the senescence of chondrocytes. (a) Schematic diagram of primary chondrocyte isolation and in vitro experimental design. (b) Representative images of brightfield, Alcian blue, Safranin O, and Toluidine blue staining of chondrocytes. (c, d) Protein levels of p16 and SLPI detected by Western blot (WB) after IL-1β treatment (c) or Slpi overexpression (OE-Slpi; d). (e, f) Representative images of SA-β-gal staining (e) and quantitative analysis of positive cells (f) in OE-negative control (OE-NC) or OE-Slpi chondrocytes. (g, h) Representative images of SA-β-gal staining (g) and quantitative analysis of positive cells (h) in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (i, j) Quantitative real-time PCR (qPCR) analysis of p16 and MMP3 mRNA expression in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (k, l) Representative images of SA-β-gal staining (k) and quantitative analysis of positive cells (l) in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. (m, n) qPCR analysis of p16 and MMP3 mRNA expression in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. Data are presented as mean ± standard deviation (n = 3 independent experiments). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant. (Student’s t -test: f; ANOVA: h, i, j, l, m, n). OE, overexpression; NC, negative control.

    Journal: Computational and Structural Biotechnology Journal

    Article Title: seneR: An R package for comprehensive senescence assessment and its application in type 2 diabetes and osteoarthritis

    doi: 10.1016/j.csbj.2025.12.031

    Figure Lengend Snippet: Verification of the therapeutic effect of PM in delaying the senescence of chondrocytes. (a) Schematic diagram of primary chondrocyte isolation and in vitro experimental design. (b) Representative images of brightfield, Alcian blue, Safranin O, and Toluidine blue staining of chondrocytes. (c, d) Protein levels of p16 and SLPI detected by Western blot (WB) after IL-1β treatment (c) or Slpi overexpression (OE-Slpi; d). (e, f) Representative images of SA-β-gal staining (e) and quantitative analysis of positive cells (f) in OE-negative control (OE-NC) or OE-Slpi chondrocytes. (g, h) Representative images of SA-β-gal staining (g) and quantitative analysis of positive cells (h) in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (i, j) Quantitative real-time PCR (qPCR) analysis of p16 and MMP3 mRNA expression in chondrocytes treated with 10 ng/ml IL-1β alone or combined with 1 μM PM. (k, l) Representative images of SA-β-gal staining (k) and quantitative analysis of positive cells (l) in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. (m, n) qPCR analysis of p16 and MMP3 mRNA expression in chondrocytes treated with H₂O₂ alone or combined with 1 μM PM. Data are presented as mean ± standard deviation (n = 3 independent experiments). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant. (Student’s t -test: f; ANOVA: h, i, j, l, m, n). OE, overexpression; NC, negative control.

    Article Snippet: For over-expression SLPI, chondrocytes were transfected with pcDNA3.1/Slpi full-length plasmid using Lipo8000 (Beyotime) according to the manufacturer’s instructions.For IL-1β treatment, mouse primary chondrocytes were treated with recombinant mouse IL-1β (10 ng/ml, MedChemExpress) for 24 h. For H2O2-induced senescence, mouse primary chondrocytes were treated with H2O2 (200 μM, MKBio Shanghai) for 2 h. For PM treatment, mouse primary chondrocytes were treated with or without PM (MedChemExpress), dissolved in DMSO (Dimethyl sulfoxide, MedChemExpress).

    Techniques: Isolation, In Vitro, Staining, Western Blot, Over Expression, Negative Control, Real-time Polymerase Chain Reaction, Expressing, Standard Deviation

    Fig. 4. Regulation of IL-24 by transcription factor AP-1. (A) RT-qPCR analysis of IL-24 mRNA expression levels in human nasal mucosal tissue samples (left, n=15) and ELISA detection of IL-24 levels in human serum samples (right, n=5). (B) Measurement of IL-24 mRNA in nasal mucosal and serum samples from HDM-sensitized AR mouse models (n=4). (C) Positive correlation between IL-24 expression and FOS and JUN levels in human nasal mucosal tissue samples. (D) Positive correlation between IL-24 expression and FOS and JUN levels in mouse nasal mucosal tissue samples. (E) Predicted AP-1 binding sites in the IL-24 promoter region and design of fragments for subsequent ChIP analysis. (F) AP-1 binding motif. (G) Confirmation of RT-qPCR products in ChIP assays using nucleic acid electrophoresis. (H) ChIP-seq data from the ENCODE database verifying AP-1 binding peaks on the promoter region of IL-24 in A549 cells. Error bars represent mean ± SD. Ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Journal: International immunopharmacology

    Article Title: House dust mite induced mucosal barrier dysfunction and type 2 inflammatory responses via the MAPK/AP-1/IL-24 Signaling pathway in allergic rhinitis.

    doi: 10.1016/j.intimp.2024.113972

    Figure Lengend Snippet: Fig. 4. Regulation of IL-24 by transcription factor AP-1. (A) RT-qPCR analysis of IL-24 mRNA expression levels in human nasal mucosal tissue samples (left, n=15) and ELISA detection of IL-24 levels in human serum samples (right, n=5). (B) Measurement of IL-24 mRNA in nasal mucosal and serum samples from HDM-sensitized AR mouse models (n=4). (C) Positive correlation between IL-24 expression and FOS and JUN levels in human nasal mucosal tissue samples. (D) Positive correlation between IL-24 expression and FOS and JUN levels in mouse nasal mucosal tissue samples. (E) Predicted AP-1 binding sites in the IL-24 promoter region and design of fragments for subsequent ChIP analysis. (F) AP-1 binding motif. (G) Confirmation of RT-qPCR products in ChIP assays using nucleic acid electrophoresis. (H) ChIP-seq data from the ENCODE database verifying AP-1 binding peaks on the promoter region of IL-24 in A549 cells. Error bars represent mean ± SD. Ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Article Snippet: Recombinant human IL-24 was obtained from MedChemExpress.

    Techniques: Quantitative RT-PCR, Expressing, Enzyme-linked Immunosorbent Assay, Binding Assay, Nucleic Acid Electrophoresis, ChIP-sequencing

    Fig. 5. IL-24 downregulates occludin and ZO-1 via the JAK/STAT1/3 pathway. (A) Phosphorylated STAT1 and STAT3 expression in human nasal mucosal samples was assessed using Western blotting (n = 3). (B) Phosphorylated STAT1 and STAT3 expression in mouse nasal mucosal samples was also evaluated using Western blotting (n = 3). (C) IL-24 mRNA expression and increased IL-24 levels in the supernatant were measured in HNEpC cells stimulated with HDM solution for 24 h (n = 3). (D) HNEpC were treated with HDM solution for 24 h, followed by re-treatment with the supernatant for another 24 h. Western blot was used to assess phos phorylated STAT1/STAT3 and TJ proteins (n = 3). (E) The expression of TJ proteins occludin and ZO-1 was significantly reduced in the HDM-treated samples, indicating compromised epithelial integrity. (F) Cell permeability was evaluated for the samples in (D); the left panel shows TEER measurements, and the right panel presents FD4 permeability assays (n = 3). (G) HNEpC cells were treated with recombinant human IL-24 protein for 24 h, followed by Western blotting to measure phosphorylated STAT1 and STAT3, as well as TJ protein expression (n = 3). (H) Results revealed a decrease in the expression of TJ proteins occludin and ZO-1 in the samples treated as indicated in (G) (n = 3). (I) Cell permeability was assessed for the samples in (G); the left panel shows TEER measurements, and the right panel presents FD4 permeability assays (n = 3). (J) STAT1 was knocked down using si-STAT1, and HNEpC cells were treated with recombinant human IL-24 for 24 h. Phosphorylated STAT1 and tight junction (TJ) protein expression were then assessed by Western blotting (n = 3). (K) HNEpC cells were treated with the STAT1 inhibitor Fludarabine and recombinant human IL-24 for 24 h. Phosphorylated STAT1 and tight junction (TJ) protein expression were then measured by Western blotting (n = 3). Error bars represent mean ± SD. ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Journal: International immunopharmacology

    Article Title: House dust mite induced mucosal barrier dysfunction and type 2 inflammatory responses via the MAPK/AP-1/IL-24 Signaling pathway in allergic rhinitis.

    doi: 10.1016/j.intimp.2024.113972

    Figure Lengend Snippet: Fig. 5. IL-24 downregulates occludin and ZO-1 via the JAK/STAT1/3 pathway. (A) Phosphorylated STAT1 and STAT3 expression in human nasal mucosal samples was assessed using Western blotting (n = 3). (B) Phosphorylated STAT1 and STAT3 expression in mouse nasal mucosal samples was also evaluated using Western blotting (n = 3). (C) IL-24 mRNA expression and increased IL-24 levels in the supernatant were measured in HNEpC cells stimulated with HDM solution for 24 h (n = 3). (D) HNEpC were treated with HDM solution for 24 h, followed by re-treatment with the supernatant for another 24 h. Western blot was used to assess phos phorylated STAT1/STAT3 and TJ proteins (n = 3). (E) The expression of TJ proteins occludin and ZO-1 was significantly reduced in the HDM-treated samples, indicating compromised epithelial integrity. (F) Cell permeability was evaluated for the samples in (D); the left panel shows TEER measurements, and the right panel presents FD4 permeability assays (n = 3). (G) HNEpC cells were treated with recombinant human IL-24 protein for 24 h, followed by Western blotting to measure phosphorylated STAT1 and STAT3, as well as TJ protein expression (n = 3). (H) Results revealed a decrease in the expression of TJ proteins occludin and ZO-1 in the samples treated as indicated in (G) (n = 3). (I) Cell permeability was assessed for the samples in (G); the left panel shows TEER measurements, and the right panel presents FD4 permeability assays (n = 3). (J) STAT1 was knocked down using si-STAT1, and HNEpC cells were treated with recombinant human IL-24 for 24 h. Phosphorylated STAT1 and tight junction (TJ) protein expression were then assessed by Western blotting (n = 3). (K) HNEpC cells were treated with the STAT1 inhibitor Fludarabine and recombinant human IL-24 for 24 h. Phosphorylated STAT1 and tight junction (TJ) protein expression were then measured by Western blotting (n = 3). Error bars represent mean ± SD. ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Article Snippet: Recombinant human IL-24 was obtained from MedChemExpress.

    Techniques: Expressing, Western Blot, Permeability, Recombinant

    Fig. 6. Blocking IL-24 protects the epithelial barrier. (A) After knockdown of IL20Rβ, HNEpC were treated with HDM solution for 24 h, resulting in a decrease in the mRNA expression of occludin and ZO-1. n = 3. (B) Western blot analysis of samples from (A) revealed the phosphorylation levels of STAT1/3 and the expression of TJ proteins. n = 3. (C) The cellular permeability of samples from (A) was assessed; the left panel shows TEER measurements, and the right panel displays FD4 permeability experiments. n = 3. (D) Schematic diagram of the AR disease model induction and stimulation in HDM-sensitized mice treated with Ruxolitinib. (E) The left panel shows the ELISA detection of serum IgE levels in mice, while the right panel presents the overall score of nasal symptoms. n = 8. (F) Representative images of H&E staining of mouse nasal mucosa, with red lines indicating the epithelial boundary of the nasal mucosa. (G) Measurement of nasal mucosal thickness in H&E- stained sections. n = 3. (H) Eosinophil counts in high-power fields of H&E-stained nasal mucosa. n = 3. (I) Western blot analysis of mouse nasal mucosa samples to assess the phosphorylation of STAT1/3 and the expression of TJ proteins. n = 3. (J) FD4 levels in NALF (n = 4) and serum (n = 8). (K) Representative images of immunofluorescence analysis of occludin and ZO-1 in mouse nasal mucosa tissue. n = 3. Error bars represent mean ± SD. ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Journal: International immunopharmacology

    Article Title: House dust mite induced mucosal barrier dysfunction and type 2 inflammatory responses via the MAPK/AP-1/IL-24 Signaling pathway in allergic rhinitis.

    doi: 10.1016/j.intimp.2024.113972

    Figure Lengend Snippet: Fig. 6. Blocking IL-24 protects the epithelial barrier. (A) After knockdown of IL20Rβ, HNEpC were treated with HDM solution for 24 h, resulting in a decrease in the mRNA expression of occludin and ZO-1. n = 3. (B) Western blot analysis of samples from (A) revealed the phosphorylation levels of STAT1/3 and the expression of TJ proteins. n = 3. (C) The cellular permeability of samples from (A) was assessed; the left panel shows TEER measurements, and the right panel displays FD4 permeability experiments. n = 3. (D) Schematic diagram of the AR disease model induction and stimulation in HDM-sensitized mice treated with Ruxolitinib. (E) The left panel shows the ELISA detection of serum IgE levels in mice, while the right panel presents the overall score of nasal symptoms. n = 8. (F) Representative images of H&E staining of mouse nasal mucosa, with red lines indicating the epithelial boundary of the nasal mucosa. (G) Measurement of nasal mucosal thickness in H&E- stained sections. n = 3. (H) Eosinophil counts in high-power fields of H&E-stained nasal mucosa. n = 3. (I) Western blot analysis of mouse nasal mucosa samples to assess the phosphorylation of STAT1/3 and the expression of TJ proteins. n = 3. (J) FD4 levels in NALF (n = 4) and serum (n = 8). (K) Representative images of immunofluorescence analysis of occludin and ZO-1 in mouse nasal mucosa tissue. n = 3. Error bars represent mean ± SD. ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Article Snippet: Recombinant human IL-24 was obtained from MedChemExpress.

    Techniques: Blocking Assay, Knockdown, Expressing, Western Blot, Phospho-proteomics, Permeability, Enzyme-linked Immunosorbent Assay, Staining, Immunofluorescence

    Fig. 7. IL-24 promotes IL-33 production. (A) Treatment of HNEpC with HDM solution for 24 hours followed by a second 24-hour stimulation resulted in increased IL- 33 mRNA expression and IL-33 levels in the supernatant (n=3). (B) Treatment with recombinant human IL-24 for 24 hours also increased IL-33 mRNA expression and supernatant IL-33 levels in HNEpC (n=3). (C) After IL20Rβ knockdown, HDM treatment of HNEpC for 24 hours led to decreased IL-33 mRNA expression and IL-33 levels in the supernatant (n=3). (D) Following 2 hours of Ruxolitinib treatment, subsequent HDM stimulation of HNEpC for 24 hours resulted in reduced IL-33 mRNA expression and supernatant IL-33 levels (n=3). (E) Serum IL-33 levels and IL-33 mRNA expression in nasal mucosa samples from mice were measured (n=3). (F) A schematic representation showing how HDM upregulates IL-24, damaging the epithelial barrier. Error bars represent mean ± SD. ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Journal: International immunopharmacology

    Article Title: House dust mite induced mucosal barrier dysfunction and type 2 inflammatory responses via the MAPK/AP-1/IL-24 Signaling pathway in allergic rhinitis.

    doi: 10.1016/j.intimp.2024.113972

    Figure Lengend Snippet: Fig. 7. IL-24 promotes IL-33 production. (A) Treatment of HNEpC with HDM solution for 24 hours followed by a second 24-hour stimulation resulted in increased IL- 33 mRNA expression and IL-33 levels in the supernatant (n=3). (B) Treatment with recombinant human IL-24 for 24 hours also increased IL-33 mRNA expression and supernatant IL-33 levels in HNEpC (n=3). (C) After IL20Rβ knockdown, HDM treatment of HNEpC for 24 hours led to decreased IL-33 mRNA expression and IL-33 levels in the supernatant (n=3). (D) Following 2 hours of Ruxolitinib treatment, subsequent HDM stimulation of HNEpC for 24 hours resulted in reduced IL-33 mRNA expression and supernatant IL-33 levels (n=3). (E) Serum IL-33 levels and IL-33 mRNA expression in nasal mucosa samples from mice were measured (n=3). (F) A schematic representation showing how HDM upregulates IL-24, damaging the epithelial barrier. Error bars represent mean ± SD. ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Article Snippet: Recombinant human IL-24 was obtained from MedChemExpress.

    Techniques: Expressing, Recombinant, Knockdown